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Abstract: Aim: This study aimed to systematically review the preclinical data of neuroprotective agents for Parkinson’s 
disease (PD) to support the translation of these compounds. 
Methods: The study consisted of two phases. In phase I, Pubmed and Scopus were systematically searched for 
neuroprotective agents for PD. In phase II, a systematic search was conducted for each substance identified in phase I. 
Articles were included if they used MPTP, 6-OHDA, rotenone or paraquat injury models. 
Results: Phase I led to the identification of 168 putative neuroprotective agents. Eventually ten compounds were included: 
melatonin, estrogen, nicotine, caffeine, riluzole, curcumin, coenzyme Q10, aspirin, EGCG and resveratrol. Phase II 
revealed 113 experimental studies and three reviews. 
Conclusion: This study clearly depicts the preclinical data of ten promising neuroprotective agents. While some of these 
compounds have already been tested in clinical use, none of them was studied in an appropriately designed trial to 
determine a neuroprotective effect. In expectation of qualitatively improved neuroprotection trials, the data from this 
study provide a firm foundation for future research. 
Keywords: Aspirin, caffeine, coenzyme Q10, curcumin, EGCG, estrogen, melatonin, neuroprotection, neuroprotective agents, 
nicotine, Parkinson’s disease, resveratrol, riluzole. 
INTRODUCTION 
 Parkinson’s disease (PD) is a progressive disease that 
damages neurons in specific dopaminergic brain areas, 
causing debilitating symptoms, such as resting tremor, 
rigidity and bradykinesia [1]. Currently, levodopa is widely 
prescribed as the first-line treatment for PD. Although 
levodopa is highly effective as a symptomatic treatment, it is 
incapable of providing the long-term protection that is 
needed to impair the onset or progress of the disease [2]. As 
a result, in the more advanced stages of this disease, patients 
develop motor complications that are not manageable with 
current treatments. Moreover, the cognitive and autonomic 
functions of patients become increasingly impaired during 
the progression of PD [3]. These non-motor complications 
seriously affect patients’ quality of life and are disabling in 
everyday life. Although the symptoms are serious, the onset 
of these complications is slow. In addition, it is estimated 
that there is a six-year time frame from the onset of neuronal 
cell loss and the emergence of clinical dysfunction [4]. This 
provides a window for disease-modifying treatments to 
prevent or delay the ongoing process of neurodegeneration. 
Since current treatments are unable to meet these  
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requirements, it is clear that there is an urgent need for novel 
neuroprotective options [2, 5]. 
 During the last decade, researchers have shown an 
increased interest in neuroprotection, resulting in a large 
volume of published studies investigating neuroprotective or 
disease-modifying agents. This emphasis has raised high 
expectations for novel neuroprotective therapeutic options 
for PD that until now have not been met [6]. However, this 
does not mean that all this research has not delivered results, 
rather, the high expectations have clouded gradual 
advancements [7]. Although disease-modifying therapies 
have not yet found their way to clinical practice, a 
substantial number of compounds have been identified as 
neuroprotective in preclinical studies. Since most physicians 
rarely access or appraise scientific evidence directly from 
research results [8], most neurologists have overlooked 
preclinical improvements, resulting in lowered expectations 
and misplaced doubts about neuroprotection. 
 The fact that only a limited number of compounds have 
been tested in clinical trials is due to several reasons—the 
most prominent is the limitations in standard clinical trials 
[5]. Since it is not possible to measure the number of 
dopaminergic neurons in vivo, most clinical trials use 
surrogate endpoints such as clinical ratings. The main 
difficulty with such endpoints is that it is nearly impossible 
to identify the difference between symptomatic and 
neuroprotective effects [5]. Therefore, new study designs 
have been recently developed, such as the delayed-start 
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design. In theory, these designs should be able to help 
differentiate symptomatic from neuroprotective effects of 
putative neuroprotective agents [5]. Furthermore, novel brain 
imaging techniques and biomarkers that monitor the loss of 
dopaminergic neurons will help to improve the quality of 
neuroprotective clinical trials [7, 9]. It is therefore reasonable 
to expect an increase in higher-quality neuroprotective trials 
in the near future [7, 10, 11]. Since the field of 
neuroprotection is wide, public reporting and data mining 
will enhance this goal [7]. It is thus important that the 
extensive literature is presented in a systematic and 
clarifying way. 
 The aim of this study is to systematically review the pre-
clinical data of neuroprotective agents to support the 
translation of these compounds from the bench to the 
bedside. 
METHODS 
 Given the abundance of published studies of 
neuroprotection, we covered the field in both a systematic 
and selective manner. We chose a review strategy similar to 
the one used by Ravina et al., [12] and Kwon et al., [13] to 
search for neuroprotective agents for PD and spinal cord 
injury, respectively. These studies consisted of two phases; 
the initial step was the identification of the most promising 
neuroprotective agents. 
 In phase I, we performed a Pubmed and Scopus search 
for “neuroprotective agents AND Parkinson’s Disease”. The 
abstracts and titles were screened for relevant compounds, 
which were then assessed by the adjusted criteria developed 
by the Committee to Identify Neuroprotective Agents in 
Parkinson’s (CINAPS) to identify the most potential agents 
[12]. Namely: 
• Safety and tolerability 
Compounds were recognized as safe when 
they were already registered as medicines 
or supplements, listed in the Generally 
Recognized as Safe (GRAS) database or 
found to be safe in clinical trials.  
• A scientific rationale  
This includes consistency of preclinical 
data and a credible mechanism of action. 
• Evidence for neuroprotection or indication 
of benefit 
This consists of positive preclinical data in 
vertebrate animals and data from human 
trials or epidemiological studies that 
suggest an association between the agent 
and a decreased risk of PD. 
 Moreover, since we aim to identify compounds that could 
be used in trials in the near future, we only included agents, 
which are already available for use in humans. This 
implicates that pipeline products were excluded, as these 
compounds are not freely available and are still under 
development. In addition, the majority of pharmaceutical 
companies only selectively publishes results for pipeline 
products, which hinders the comprehensive evaluation of 
these compounds. Another group of substances that was 
excluded were those that are currently prescribed for PD, 
such as dopamine receptor agonists or MAO-B inhibitors. 
Like Ravina et al., [12], when multiple compounds from the 
same class were identified, we chose the most promising one 
for detailed evaluation. 
 Following compound identification in phase I, we 
performed a systematic literature review in phase II for each 
therapy in Pubmed and Scopus, using the “agent name” 
AND “Parkinson OR parkinsonism*” AND “neuroprotection 
OR neuroprotective OR disease-modifying” as search strings 
(date: 19-01-2011). We then applied the following exclusion 
criteria: 
• Studies that utilized injury models other than MPTP, 
6-OHDA, rotenone or paraquat were excluded 
• Studies that used invertebrate animal models were 
excluded 
• Studies that did not systematically administer the 
agent were excluded 
• Studies that did not aim to provide neuroprotection 
were excluded 
 In addition, we evaluated reference lists from the most 
recent articles in order to find additional studies that were 
not identified during the initial search. For agents that were 
recently reviewed, we provided an overview of the most 
important conclusions and augmented the conclusions of 
each study by reporting data from these more recent studies. 
The data from the resulting studies for all other agents were 
placed in a table accompanied by a summary text to provide 
a clear overview of all the preclinical data for each 
neuroprotective agent. 
INJURY MODELS 
 In order to better comprehend the results of this 
systematic review, the main features of the included injury 
models are described below. Currently, several neurotoxins 
are available to induce experimental parkinsonism in 
animals. In this review, the four most frequently utilized 
methods are included, since they are generally considered as 
the best validated models. All four of these neurotoxins are 
capable of inducing the pathological hallmark of PD, 
neuronal cell loss in the substantia nigra (SN) [14]. The main 
contributing factor to this cell loss is mitochondrial 
dysfunction by inhibiting complex I, resulting in oxidative 
stress and eventually cell death (Fig. 1) [15]. 
1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) 
 MPTP is a commonly used neurotoxin for inducing PD in 
rodent and primate models since the discovery of its ability 
to cause parkinsonism in men [16]. MPTP is a lipophilic 
protoxin that rapidly crosses the blood-brain barrier (BBB) 
[17], where it selectively destroys dopamine (DA) neurons in 
the SN [18]. Extensive research has led to a relatively clear 
understanding of the mechanisms of action. Once MPTP 
crosses the BBB, it is rapidly converted by a combination of 
mono-amino oxidase B (MAO-B) and other oxidation 
processes into the toxic MPP+ [19]. MPP+ is taken up via 
the dopamine transporter (DAT) into DA neurons where it 
triggers the formation of reactive oxygen species (ROS) 
[20]. Next, it accumulates inside the mitochondria and 
impairs the mitochondrial respiration by inhibition of 
complex I [21]. This leads to a combination of a reduction in 
cellular ATP and a further upregulation of ROS, which 
initiates cell death-related signalling pathways. Since rats do 
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not have sufficient MAO-B in the brain to convert MPTP, 
they are not suited for MPTP induced PD. However, some 
investigators directly inject MPP+ into rat brains. Because 
the mechanisms of MPTP intoxication are quite similar to 
features seen in PD, the MPTP model is seen as a valid PD 
model [14]. 
6-Hydroxydopamine (6-OHDA) 
 Together with MPTP, 6-OHDA is the most widely 
utilized neurotoxin to create PD models. In contrast to 
MPTP, 6-OHDA does not readily cross the BBB. Therefore, 
direct injection of 6-OHDA into the brain of test animals is 
necessary [14]. Currently, the mode of action is thought to be 
via increased oxidative stress and mitochondrial dysfunction, 
although the exact mechanism remains under discussion. It is 
clear, however, that administration of 6-OHDA leads to its 
conversion into ROS [22], a reduction of the antioxidant 
glutathione (GSH) and antioxidant enzyme superoxide 
dismutase (SOD) [23], elevated levels of iron in the SN [24] 
and inhibition of complex I and IV in the mitochondria [25], 
which leads to further oxidative stress. 6-OHDA lesions 
share common mechanisms of action with PD and is 
therefore regarded as an excellent model [14]. 
Rotenone 
 Rotenone was assessed in 2000 because of its MPTP-like 
inhibition of mitochondrial complex I [14]. However, since 
its introduction, rotenone has been under serious debate [26]. 
Like MPTP, rotenone readily crosses the BBB, where it 
causes oxidative stress and accumulates inside the 
mitochondria dopaminergic neurons. However, the resulting 
reduction in ATP is not a cause of cell death. Rather, a large 
amount of ROS accounts for the damage in the SN region 
[27]. One important benefit of the rotenone model is that 
some investigators have reported the accumulation of ?-
synuclein, one of the main characteristics of PD, while 
MPTP and 6-OHDA are unable to induce this accumulation. 
In addition to rotenone’s central effects, it also exerts 
systemic toxicity leading to cardiovascular events and 
gastrointestinal complications. This causes a high mortality 
rate of 30% in all treated animals. In addition, some rats 
seem to show an intrinsic resistance to rotenone (only 50% 
show neurodegeneration). Since experiments with rotenone 
require a large group of animals [28], this model is not 
preferred by most investigators, although it resembles 
specific PD hallmarks that are not induced by MPTP or 6-
OHDA [14]. 
Paraquat and Maneb 
 The herbicide paraquat and fungicide maneb have been 
associated with an increased incidence of PD [29]. 
Therefore, investigators have tried to create a model for PD 
with the use of these agents. Paraquat is transported through 
the BBB by a neutral amino transporter. Transport into the 
cell is regulated by Na+-dependent reuptake [30], whereafter 
paraquat intoxicates the mitochondria by redox cycling and 
directly inhibits complex I [31]. Maneb, on the other hand, 
intoxicates the mitochondria by inhibiting complex III [14]. 
Progressive weight loss and respiratory problems account for 
a relatively high mortality rate [32]. Furthermore, the degree 
of neuronal cell death is minimal and variable [31]. For these 
reasons, the use of the paraquat/maneb model is limited [14]. 
However, paraquat and maneb induce toxicity gradually, 
which mimics the onset of PD better than the other 
neurotoxins [33]. 
RESULTS 
 Phase 1 of this review was conducted in December 2010 
and identified 168 putative neuroprotective agents. After 
applying the CINAPS criteria and all exclusion criteria, 10 
neuroprotective agents were included in a systemic literature 
review in phase II (i.e. melatonin, estrogen, nicotine, 
 
Fig. (1). Mechanisms of action of the neurotoxins MPTP, 6-OHDA, maneb and rotenone. MPTP is converted into MPP+ after which it enters 
the dopaminergic neuron by the dopamine transporter (DAT). The same transporter is utilized by 6-OHDA to enter the cell. Paraquat enters 
the neuron by a natrium-dependent transporter (Na-dep transporter) and rotenone and maneb cross the cell membrane by diffusion. Once 
inside the cell, all neurotoxins inhibit the mitochrondial complex I or complex III, impairing the mitochondrial respiration. Eventually this 
leads to a decrease in ATP and an increase in reactive oxygen species (ROS), finally resulting in dopaminergic cell death. 
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caffeine, riluzole, curcumin, coenzyme Q10, aspirin, EGCG 
and resveratrol). The systematic review, conducted in 
January 2011, resulted in 548 potentially relevant studies. 
Using the above mentioned exclusion criteria, we included 
113 studies for in-depth evaluation. Fig. (2) schematically 
depicts the process. For each neuroprotective agent (with the 
exception of recently reviewed agents) a table with important 
features of the studies was composed (see Supplementary 
Material) with an accompanying summary text. 
Nicotine 
 Various prospective studies have suggested a strong 
association between tobacco smoking and a decreased risk of 
PD [34]. Nicotine is one of the main constituents of tobacco 
and is known for its pharmacological effects, influencing the 
cholinergic nicotinic receptors in both the central and 
peripheral nervous system. 
 Substantial research has been conducted to investigate 
the putative neuroprotective properties of nicotine and the 
literature search revealed a total of 27 papers [35-61]. Quik 
et al., [62] reviewed the effects of nicotine on toxin-induced 
toxicity in rats, mice and non-human primates. The authors 
found that chronic intermittent administration of nicotine in 
non-human primates was partially neuroprotective. 
Furthermore, both intermittent and constant administration 
of nicotine in rats was shown to be neuroprotective, although 
it depended on the lesion size and location. In contrast with 
the results in monkeys and rats, data from studies in mice are 
controversial. Most studies that used intermittent dosage 
schemes found neuroprotective effects, whereas Quick et al., 
demonstrated that constant administration was not effective 
in mice. An important difference is that most mice were 
lesioned by MPTP, while 6-OHDA was utilized in rats. This 
suggests that nicotine might be more protective against 6-
OHDA-induced toxicity than MPTP. Other possible 
confounding differences are the plasma half-life of 
nicotine—5-10 min in mice, 1-2h in rats and monkeys—and 
the variation in distribution of nicotinic receptor subtypes. 
Several articles published before 2007 were left out in Quik 
et al.’s review, but the data from these earlier studies support 
their conclusions [37, 41, 46, 49, 51, 57]. Furthermore, the 
systematic search identified two papers published after 2007 
that fitted the criteria of this systematic review [44, 60]. 
Takeuchi et al., [60] conducted an experiment with rotenone-
induced toxicity in mice. They showed that nicotine pre-
treatment significantly protected the striatum and substantia 
nigra from the deleterious effects induced by rotenone. Other 
investigators demonstrated that nicotine pretreatment was 
effective in rats and monkeys, but that posttreatment was not 
able to protect the animals [44]. 
 It is noteworthy that a recent clinical trial among six male 
PD patients demonstrated that chronic high doses of nicotine 
 
Fig. (2). Schematic overview of a systematic literature review of neuroprotective agents for Parkinson’s disease. Phase 1—identification of 
potential neuroprotective agents. Phase 2-identification of relevant preclinical studies for each agent. 
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improved motor scores, reduced dopaminergic treatment and 
had a potential beneficial effect on striatal dopamine 
transporter density [63, 64]. Moreover, the authors reported 
that adverse effects were common but moderate and were 
pharmacologically manageable. 
 To conclude, the sum of epidemiological and preclinical 
data strongly suggests that nicotine has neuroprotective 
properties. The addition of encouraging results from a small-
scale observational study elects nicotine as a strong 
candidate for large-scale neuroprotective clinical trials in the 
near future. 
17?-Estradiol 
 17?-estradiol (E2) is a predominant female sex hormone 
with influences throughout the entire body. Since several 
epidemiological studies have shown a greater incidence of 
PD in men than women, extensive research is performed to 
investigate the possible neuroprotective effects of E2 [65, 
66]. Since the compound is natural it is not patent protected. 
Several patents have been filed on its use for neuroprotection 
with Parkinson’s disease and other neurodegenerative 
diseases since 2001 (WO02087552, and WO02069975). 
 Our systematic review resulted in 22 studies that fitted 
our criteria [67-88]. Bourque et al., [89] reviewed all 17 
studies where MPTP models were utilized in 2009 [68, 70-
73, 75, 76, 79-88]. They found that E2 is neuroprotective in 
MPTP mice models of both sexes when given pre- or post-
injury with a physiological concentration (102 pg/ml). 
However, multiple higher doses of E2 or a single higher dose 
before MPTP injection did not show a neuroprotective 
effect. Two studies were not included in the review [67, 74] 
and three other studies conducted with the 6-OHDA-injury 
model [69, 78, 90] further support the conclusions drawn in 
the review by Bourque et al., [89]. Murray et al., [69] 
reported that E2 treatment in female ovariectomized 
Sprague-Dawley rats decreased their lesions, but increased 
lesions in male gonadectomized Sprague-Dawley rats. 
Quesada and Micevych [77] partially supported these results 
by showing that ovariectomized female Long-Evans rats 
were protected against 6-OHDA lesioning by estrogen 
pretreatment. In contrast, Ferraz et al., [78] demonstrated no 
effect of E2 on 6-OHDA-induced tyrosine hydroxylase 
(TH)-cell loss in ovariectomized female Wistar rats. These 
inconsistent results for 6-OHDA studies could be due to 
differences in the locations of 6-OHDA injections, namely 
SN pars compacta (SNpc) vs. medial forebrain. Although all 
three 6-OHDA studies administered doses above the 
physiological range, Ferraz et al., [78] used the highest dose, 
supporting the conclusion that doses in the physiological 
range are more effective. Also, the duration of Ferraz et al.’s 
[78] study was longer than the others, which could imply 
that E2 only protects for a limited time in the 6-OHDA 
model. 
 Four clinical trials with E2 have been performed among 
post-menopausal women with PD [91-94]. These studies 
reported positive results on symptomatic endpoints, but did 
not measure neuroprotection. 
 Overall, the majority of E2 studies showed promising 
neuroprotective properties in vivo. Furthermore, the 
association between a lower risk of PD and women appears 
to indicate that E2 is a promising compound. Unfortunately, 
no attention has been paid to the effects of E2 in paraquat 
and rotenone models; thus, future research should focus on 
these models. 
Melatonin (Supplementary Material Table A1) 
 Melatonin is an indoleamine mainly synthesized from 
tryptophan in the human pineal gland and has been 
associated with circadian and seasonal rhythms. However, it 
is associated with many more processes, including 
neuroprotection. 
 Twenty-two papers have reported on the neuroprotective 
properties of melatonin in vivo [33, 95-115]. In 2005, Mayo 
et al., [116] conducted a literature review including 10 
papers on this subject [95, 96, 99-103, 110-112]. The authors 
summarized the results of in vivo studies conducted from 
1995-2004. The studies were performed in both MPTP and 
6-OHDA models and uniformly showed decreased neuron 
loss and increased DA levels with melatonin treatment. This 
led to the conclusion that melatonin was an agent with 
significant neuroprotective promises. However, the review 
did not include three studies with negative outcomes [105, 
113, 114]. These investigators failed to show a 
neuroprotective effect of melatonin in MPTP-treated mice. 
 After Mayo et al.’s [116] review, nine other studies were 
performed. In 2006, Sharma et al., [107] demonstrated an 
increasing effect of a high dose of melatonin on the TH-
immunoreactivity in a 6-OHDA-rat model. A lower dose 
failed to show an effect in this study. In the same year, 
Saravanan et al., [106] conducted a study on the effects of 
melatonin on rotenone-injured rats. They showed that 
melatonin was protective against rotenone-induced 
cytotoxicity in neuron cells and in case of GSH depletion. 
The authors also measured higher activity of SOD and 
catalase in the brain when melatonin was administered. 
These results were supported by another rotenone study in 
which rats chronically exposed to rotenone were protected 
by co-treatment with melatonin [115]. In the same year, 
Capitelli et al., [98] conducted an MPTP test in rats. One 
dose of melatonin (50mg/kg) protected the rats against the 
MPTP-induced TH neuron depletion after 24 hours, but no 
effect was measured after seven days. The same situation 
accounted for the results of the open field test. The 
investigators suggested that this could be due to low levels of 
circulating melatonin after seven days. Borah and 
Mohanakumar [97] hypothesized that parkinsonian 
neurotoxins that generate •OH in a DA-enriched 
environment would be inducive to the production of 6-
OHDA and melatonin may act as a potent free radical 
scavenger, thereby protecting against 6-OHDA toxicity. The 
authors found support for this hypothesis in an experiment 
using levodopa and melatonin (30 mg/kg) on MPTP mice. 
Ma et al., [104] provided further evidence for the cell-
sparing effect of melatonin in the SNpc (20mg/kg) with an 
experiment in MPTP mice. Tapias et al., [109] investigated 
the presence and role of nitric oxide synthase (NOS) 
isoforms in SN and the effect of melatonin (20 mg/kg) on 
NOS activity and mitochondrial dysfunction in another 
MPTP mice model. They found increased inducible 
NOS/inducible-mitochondrial NOS activity, nitrite levels, 
oxidative stress and complex I inhibition due to MPTP 
administration. In accordance to earlier studies, melatonin 
Neuroprotection in Parkinson’s Disease The Open Pharmacology Journal, 2012, Volume 6    17 
effectively counteracted these effects. Upon supporting 
evidence for the neuroprotective role of melatonin in the 
MPTP model, Tapias et al., [108] conducted a study using a 
rotenone model. Contradictory to the study of Saravanan et 
al., in 2006 [106], Tapias et al., [108] found a potentiating 
effect of melatonin (10 mg/kg) on rotenone toxicity, leading 
to additional striatal cell loss and DA depletion. Tapias et al., 
[108] explained the differences between the two studies as a 
result of differing endpoint measurements. They further 
stated that the contradiction between their rotenone study 
and most studies in MPTP and 6-OHDA studies was due to 
the downregulating effect of melatonin on DAT, which is a 
necessary transporter for MPTP and 6-OHDA toxicity, but 
not for rotenone. However, the results of Singhal et al., [33] 
did not support this explanation. Singhal et al., [33] used a 
paraquat/maneb injury in mice and found that melatonin (30 
mg/kg) was effective in preventing DA depletion and TH-
positive neuron degeneration. Because paraquat enters the 
cell via Na
+
-dependent uptake and not DAT, the 
neuroprotective effect was not due to the downregulation of 
DAT. This implies that melatonin, independent of DAT 
downregulation, has neuroprotective properties. 
 Three clinical trials using melatonin for PD patients were 
retrieved [117-119]. Shaw et al., [117] conducted a trial in 
four patients, but no notable effect was observed. Dowling et 
al., [118] and Medeiros et al., [119] conducted two clinical 
trials with melatonin to test the effect on sleep deprivation. 
They both concluded that there was a slight improvement, 
but Medeiros et al., did not find a significant improvement in 
motor function and Dowling et al., did not measure this 
feature. Both studies did not mention any serious side 
effects. 
 In summary, 18 of 22 studies in PD models demonstrated 
neuroprotective properties of melatonin, which makes it a 
substance with strong potential. Because of the positive 
outcomes in rodent models, primate experiments are 
recommended in order to provide further evidence. 
Caffeine (Supplementary Material Table A2) 
 Caffeine is the most widely used psychoactive substance 
in the world due to its presence in coffee and other beverages 
[120]. Several epidemiological studies have linked coffee 
intake with a lower incidence of PD, suggesting 
neuroprotective properties for caffeine [121-123]. Multiple 
preclinical studies have been conducted to investigate this 
putative neuroprotective feature of caffeine. 
 The systematic review identified eight papers that 
reported on one of the four injury models and the effects of 
caffeine [124-131]. Chen et al., [125] found that caffeine (10 
mg/kg) was neuroprotective when administered 10 minutes 
prior to four injections of MPTP. Caffeine attenuated the 
depletions in striatal DA, 3,4-Dihydroxyphenylacetic acid 
(DOPAC) and in DAT-binding sites. Xu et al., [131] were 
then motivated to investigate whether this effect would be 
subject to tolerance effects, as it is with the stimulatory 
effects of caffeine. They found that repeated daily intake of 
caffeine, which resulted in locomotor tolerance, did not 
attenuate the protective effects of caffeine on the MPTP-
induced toxicity. The neuroprotective effects were then also 
established in a 6-OHDA model [126]. After several 
epidemiological studies suggested an interaction between 
estrogen and caffeine, Xu et al., [130] explored this 
association in a MPTP mouse model with both female and 
male mice. They found that, similar to previous results, 
caffeine attenuated the toxic effects of MPTP in male mice 
in a dose-dependent manner. In contrast, this result was not 
found in female mice and estrogen treatment also prevented 
this effect in young male mice. These data indicate a 
biological relationship between estrogen and caffeine for the 
risk of developing PD. In 2006, Aguiar et al., [124] showed 
that caffeine treatment after, instead of prior to, 6-OHDA 
injury was also protective. This finding was further 
supported by Singh et al., who investigated post- and pre-
injury treatment of caffeine in a MPTP model [128]. Xu et 
al., [129] then investigated the specific effective time frame 
for caffeine and reported that 30 mg/kg was effective 2h 
prior to and 2h after MPTP injection. In addition, the authors 
showed that the most important metabolites of caffeine, 
paraxanthine and theophylline, were also neuroprotective. To 
further refine the neuroprotective evidence for caffeine, 
Kachroo et al., [127] carried out a study in paraquat- and 
maneb-treated mice. Their results demonstrated that caffeine 
at 20 mg/kg significantly protected TH-positive neurons in 
both pretreatment and posttreatment. 
 Altogether, these data imply that caffeine is a strong 
neuroprotectant in rodents for various injury models. 
Furthermore, precise pairing between toxins and caffeine 
treatment may not be necessary, since caffeine’s effects are 
extended by its metabolites. Since caffeine has been 
extensively investigated in rodents, future research should 
concentrate on its effects in primates to establish firm 
evidence for future clinical trials. 
Riluzole (Supplementary Material Table A3) 
 Riluzole is a selective Na
+
-channel blocker. It is 
registered for the treatment of amyotrophic lateral sclerosis 
(ALS) and is approved for use in the United States as Rilutek 
since 1996. The patent for this application was first filed by 
Rhone-Poulenc (now part of Sanofi Aventis) on 06-03-1992 
(FR9202696). 
 Seven studies that fitted the criteria of this review were 
identified [132-138]. In 1994 three distinct studies were 
performed with riluzole in mice [133-135]. Jones-Humble et 
al., [133] investigated riluzole (33 mg/kg) in combination 
with MPTP. Unfortunately they found no significant 
difference in striatal DA levels compared to the MPTP-
injured group. Boireau et al., [134, 135] conducted two 
studies in 1994, which investigated riluzole in rats with 
MPP+ and mice with MPTP. In rats, a single dose (8 mg/kg) 
pre-injury significantly antagonized the MPP+-induced 
decrease in DA, but had no effect on extracellular DOPAC 
and homovanillic acid (HVA) levels [135]. In mice, Boireau 
et al., [134] showed that multiple doses of riluzole (5 mg/kg) 
were able to protect against MPTP-induced depletions in 
DA, DOPAC and HVA. The discrepancy in results from 
Boireau et al., and Jones-Humble et al., could be because the 
latter utilized a very high dose, which could have hindered 
the results. Another investigation demonstrated the effects of 
two subcutaneous injections of riluzole (8 mg/kg) in 
combination with a 6-OHDA injury in rats [137]. Riluzole 
attenuated the behavioural and biochemical deficits induced 
by 6-OHDA. The same researchers investigated whether 
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reported riluzole neuroprotection in combination with MPTP 
was due to interference with MPP+ production by MAO-B 
inhibition [136]. They concluded that riluzole had no effect 
on MPP+ production; hence the observed protective effects 
were not caused by interference with MPTP metabolism. 
Araki et al., [132] further confirmed the protective effect of 
riluzole in MPTP-treated mice. They showed that this effect 
could be partially due to astrocyte activation. Following the 
studies in rodents, Obinu et al., [138] investigated riluzole in 
primates and showed that riluzole-treated marmosets 
preserved a better motor function and neurological 
performance when compared to those treated with MPTP. 
 To date, two clinical trials with riluzole have been 
performed with PD patients [139, 140]. A pilot study showed 
that riluzole was well tolerated at 100 mg/day [139]. The 
second study investigated the effects on dyskinesia and the 
duration of the ON state [140]. Although riluzole extended 
the ON duration, this did not reach significance. 
 In short, riluzole has proven its neuroprotective effects in 
rodents and in a primate model. However, little is known 
about the effects on rotenone- and paraquat-induced toxicity. 
Once this gap of evidence is addressed, both the preclinical 
and the clinical results indicate the need for larger scale, 
longitudinal clinical trials. 
Coenzyme Q10 (Supplementary Material Table A4) 
 Coenzyme Q10 (CoQ10) is a lipophilic, vitamin-like 
substance, also known as ubiquitone. It is well known for its 
function as a co-factor in the electron transport chain in 
complex I/II and its antioxidative effects. 
 Since 1995, seven preclinical studies have been 
conducted in order to investigate the neuroprotective effects 
of CoQ10 [141-147]. Schulz et al., [143] published a study 
on CoQ10 pretreatment (400 mg/kg) in MPTP mice, which 
did not show it to be protective and even worsened the 
symptoms in the experimental group. These results did not 
discourage a part of the research group, who performed 
another study [144]. In this investigation with MPTP mice, 
the investigators demonstrated a protective effect of a 200 
mg/kg CoQ10 pre- and posttreatment on DA levels and TH-
immunoreactive (IR) neuronfibers. Horvath et al., [142] 
continued the research on the neuroprotective properties of 
CoQ10 in a primate MPTP model. They reported a complete 
protective effect against dopaminergic cell loss by 
administrating 15-22 mg/kg of CoQ10. After five years a 
preclinical study was conducted by Abdin and Hamouda 
model [146] in a rotenone rat. CoQ10 (200-600 mg/kg) 
resulted in an increase in ATP levels and complex I activity, 
which had both been depleted as a result of rotenone 
treatment. In the same year, members of the research group 
from the first two studies, reported a dose-response study of 
CoQ10 (400-4800 mg/kg) in a chronic MPTP mice model 
[141]. However, CoQ10 was only effective in a dose of 1600 
mg/kg to counteract the MPTP-induced DA depletion, TH-
neuron degeneration and ?-synuclein induction. Somayajulu-
Ni?u et al., [147] demonstrated the effect of CoQ10 in 
paraquat-treated rats. A solution of 50 mg/kg of CoQ10 was 
reported to be effective in protecting against GSH depletion, 
TH-neuron degeneration and lipid peroxidation elevation. 
Yang et al., [145] assessed the combination of creatine and 
CoQ10 (1600-2000mg/kg) in MPTP mice and found a 
neuroprotective effect for both CoQ10 and creatine, as well 
as a synergetic effect when the two were combined. Notably, 
major differences were seen in the treatment dosages across 
studies. No author gave an explanation for the variation in 
effectiveness of the various doses. 
 Since 1997 there have been seven clinical trials to 
determine the symptomatic effect of CoQ10 [148-154]. The 
results of these studies are not conclusive. Shults et al., [149, 
151] and Müller et al., [150] recommended further 
investigation of positive symptomatic outcomes, but Strijks 
et al., [148] and Storch et al., [152] failed to show an effect 
on symptomatic outcomes. 
 CoQ10 has been shown to be an effective 
neuroprotective agent in several injury models. However, 
this evidence is based on a wide array of therapeutic doses. It 
has been tested as a safe substance in both animals and 
humans, but remarkably, no studies have been conducted in 
the 6-OHDA-injury model and primates. In order to validate 
a new clinical trial in humans, studies in these injury models 
have to be performed and a standard neuroprotective dose 
has to be determined. 
Curcumin (Supplementary Material Table A5) 
 Curcumin is an active polyphenolic compound of 
turmeric (Curcuma longa), which is extensively used as 
dietary spice in Indian food. In Western society, curcumin is 
used as a food additive because of its yellow colouring 
properties. Furthermore, curcumin is well known for its 
medicinal use in traditional Indian and Chinese medicine and 
several pharmacological properties have been established, 
including anti-inflammatory, antioxidant and anticarcogenic. 
 A total of six studies were identified in the systematic 
review [155-160]. Curcumin (3 x 50 m/kg) was investigated 
for the first time by Vajragupta et al., [158] using the MPTP 
injury model in mice. The posttreatment resulted in a 
significant attenuation of the MPTP-induced depletion in 
striatal DA and neuronal cell loss. Zbarsky et al., [160] 
utilized the same dose of curcumin to treat rats prior to 6-
OHDA injection. They showed that this pretreatment also 
protected the rats from neuronal cell loss and from depletion 
of DA and DOPAC. Rajeswari et al., [156] further 
elucidated the protective effects of curcumin. The authors 
demonstrated that pretreatment with 80 mg/kg of curcumin 
prevented MPTP-induced elevations in lipid peroxidation, 
SOD and catalase (CAT) activity and depletion of GSH 
levels in mice, which clearly shows the antioxidant 
properties of curcumin. The same research group reproduced 
their experiment with curcumin and one of its main 
metabolites, tetrahydrocurcumin [157]. Both compounds 
were shown to decrease depletion of striatal DA and 
DOPAC when administered prior to MPTP. Yu et al., [159] 
demonstrated that posttreatment of curcumin restored motor 
deficits and neuronal damage in MPTP-treated mice. 
Moreover, they showed that curcumin was also able to 
inhibit the c-Jun N-terminal kinase (JNK) pathway, 
suggesting that its neuroprotective effect is not only due to 
its antioxidant properties. Recently, another investigation by 
Khuwaja et al., [155] demonstrated the neuroprotective 
effects of pretreatment with curcumin in the 6-OHDA model 
in rats. Both motor deficits and neuronal damage were 
prevented by curcumin, which also had beneficial effects on 
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the antioxidant status, with increasing GSH levels and 
activity of antioxidant enzymes. Notably, Rajeswari and 
Sabesan [157] found that curcumin inhibited MAO-B 
activity, which prevents the conversion of MPTP to its toxic 
metabolite MPP+. Therefore, the neuroprotective effects of 
curcumin in both studies by Rajeswari et al., are difficult to 
interpret. Since other studies utilized 6-OHDA or 
administered curcumin after MPTP injection, this does not 
apply to them. Although the MAO-B inhibiting activity of 
curcumin is problematic in the MPTP model, this action does 
have beneficial effects for PD patients since it inhibits the 
breakdown of DA. 
 To sum up, curcumin has proven neuroprotective effects 
in the 6-OHDA and MPTP models in rodents. Its antioxidant 
properties, in particular, seem to protect neurons from toxin-
induced damage. However, considerably more work will 
need to be done to provide definitive evidence of curcumin’s 
disease-modifying capabilities, specifically studies in 
primates and using the rotenone and paraquat injury models. 
Moreover, since curcumin is frequently used in Indian food 
or as a colour additive, theoretically it is possible to conduct 
an epidemiological study to further determine the association 
between curcumin intake and the risk of developing PD. 
Aspirin (Supplementary Material Table A6) 
 Inflammation is believed to be one of the important 
factors in the pathogenesis of PD. Moreover, it has been 
demonstrated that the enzyme cyclooxygenase (COX) and 
other inflammatory proteins are elevated in PD. Therefore, 
there has been significant interest in non-steroidal anti-
inflammatory drugs (NSAIDs), especially aspirin. 
 Six studies were identified that fitted the above 
mentioned criteria [161-166]. The first study that identified a 
putative neuroprotective feature of aspirin was conducted by 
Aubin et al., [161]. The authors reported that 60 and 100 
mg/kg, but not 30 mg/kg, of aspirin administered one hour 
prior to injury to mice, attenuated the MPTP-induced 
depletion in striatal DA in a dose-dependent way. In 
addition, they investigated the time course in which aspirin 
(100 mg/kg) administration was protective and showed that 
injection with aspirin from two hours before to two hours 
after injury significantly protected the mice. It is noteworthy 
that Aubin et al., found the selective COX1 inhibitor 
indomethacin to be ineffective. Teismann and Ferger [166] 
further tried to determine if COX1 or COX2 inhibition 
accounted for the neuroprotective effects of aspirin by 
treating mice with aspirin (10, 50 or 100 mg/kg) and the 
COX2 selective inhibitor meloxicam (2, 7.5 or 50 mg/kg) 
immediately before MPTP injection. They found that both 
drugs were able to protect mice from MPTP-induced 
toxicity. Consistent with Aubin et al.’s [161] data, only 50 
and 100 mg/kg of aspirin were effective, whereas 10 mg/kg 
was ineffective. No difference in the effect of aspirin and 
meloxicam was found, suggesting that aspirin has an 
additional free radical scavenging property in addition to 
COX2 inhibition. Maharaj et al., [164] further established 
this effect. In their study, aspirin (100 mg/kg) and 
paracetamol (100 mg/kg) prevented KCN-induced 
superoxide generation and lipid peroxidation. While 
paracetamol was a more effective antioxidant, aspirin 
completely blocked the debilitating effects of MPP+ on 
striatal DA in rats, whereas paracetamol was only able to 
partially block this effect. The same research group found 
that aspirin was able to significantly attenuate mitochondrial 
dysfunction in MPP+ infused rats, preventing the formation 
of ROS [165]. Also in 2006, the effects of aspirin 
pretreatment (100 mg/kg) on a combination of MPP+ and 6-
OHDA injury in rats were investigated, utilizing 
microdialysis to determine the in vivo effects [162]. They 
demonstrated that aspirin was effective in both injury 
models, which was associated with ROS scavenging in the 6-
OHDA model, but not in the MPP+ model. Conversely, 
Gören et al., [163] did not find a neuroprotective effect of 
aspirin in the 6-OHDA model. Since they used a single 
nasogastric administration of aspirin (100 m/kg) they 
speculated that they did not reach the effective dose required. 
 Interestingly, to date, no clinical trials among PD patients 
have been performed with aspirin, but several 
epidemiological studies have been published. A meta-
analysis of six studies that investigated aspirin use and PD 
prevalence found no significant beneficial effect of aspirin 
[167]. The authors pointed out, however, that several sources 
of bias could cloud these results and thus further research is 
recommended. 
 To conclude, aspirin has been found to be 
neuroprotective in mice and rats with various injury models. 
These results are, however, not yet reproduced in primates 
and other injury models. Also, epidemiological studies have 
failed to establish a strong association between aspirin use 
and a lower prevalence of PD. Thus it is clear that aspirin 
has potential as a disease-modifying agent for PD, but future 
studies, especially with rotenone and paraquat, are warranted 
to establish a greater degree of accuracy on this subject. 
Epigallocatechin Gallate (EGCG; Supplementary 
Material Table A7) 
 EGCG, a catechin ubiquitously found in plants, is an 
important substance in green tea. It has been ascribed a wide 
range of therapeutic properties, including neuroprotection. 
Interestingly, there are several epidemiological studies that 
investigated an association between tea and PD [168, 169]. 
Among tea drinkers, the risk of developing PD was lower 
than in non-tea drinkers. This effect was thought to be 
especially influenced by EGCG. 
 The systematic review revealed four papers published 
from 2001 to 2010 that investigated the effects of EGCG in 
rodents [170-173]. Levites et al., [172] conducted a study to 
investigate the effect of green tea (0.5-5 mg/kg EGCG) and 
EGCG (2-10mg/kg) on neurodegeneration in MPTP-treated 
mice, which showed a protective effect against DA and TH 
depletion. In addition, green tea prevented MPTP-induced 
neuron loss and inhibited the upregulation of striatal SOD 
and catalase enzymes. Following this study, Choi et al., 
demonstrated similar results for neuron loss, DA and TH 
levels with 25 mg/kg EGCG administered by oral gavage 
and as green tea [170]. Also, they showed protection against 
the decreasing effects of MPTP administration on DOPAC 
and HVA levels. Seven years later, Leaver et al., noticed the 
need for an in vivo study for the 6-OHDA model in rats 
[171]. However, the administered EGCG (1-2mg/kg) did not 
show an effect on neuron loss or DA levels. Furthermore, 
they investigated the behavioural effects and reported mild 
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improvements of EGCG-treated rats in curling bias and time 
to cross the beam tests compared to 6-OHDA lesioned rats, 
which were only significant at specific time points. 
Reznichenko et al., [173] reported the results of a 
combination therapy of rasagiline and EGCG. They showed 
an effect on DA levels in MPTP-treated mice with a dose of 
10 mg/kg EGCG, but not with lower doses. Interestingly, the 
authors demonstrated neuroprotection with a combination of 
subeffective doses of EGCG and rasagiline. 
 In overview, the three MPTP studies showed promising 
results. Although Leaver et al., [171] failed to show positive 
outcomes, this could be explained by their use of a different 
injury model than other researchers and the relatively low 
dose. Further investigation is recommended in order to 
completely understand the neuroprotective effects of EGCG 
in rodents. 
Resveratrol (Supplementary Material Table A8) 
 Resveratrol (RES), a polyphenol compound, is found in 
grapes and nuts and is an important component of red wine. 
Only recently, there has been an increasing interest in the 
anti-inflammatory, anti-oxidant and neuroprotective 
properties of RES. Patents have been filed on the use of 
resveratrol with Parkinson’s disease and other 
neurodegenerative conditions since 1999 (WO2003103583 
and WO9959561). 
 The systematic review resulted in four studies for which 
the neuroprotective effects of RES in PD were assessed 
[174-177]. In 2008, in a parallel effort, three independent 
research groups tried to determine the protective effects of 
resveratrol [174-176]. Both Lu et al., [175] and Blanchet et 
al., [174] investigated resveratrol treatment in combination 
with an MPTP injury in mice. Lu et al., [175] found that 
resveratrol administration (20 mg/kg) significantly 
attenuated the cytotoxicity evoked by MPTP, which included 
motor impairment and severe neuronal damage. Consistent 
with these results, Blanchet et al., [174] showed that 
resveratrol pretreatment (50 and 100 mg/kg) prevented 
neuronal cell loss in the SN and striatal DA depletion. Also, 
resveratrol posttreatment (10-40 m/kg) was found to be 
neuroprotective in the 6-OHDA-injury model in rats as 
reported by Jin et al., [176], although they found no apparent 
dose-dependent effect. They also showed that resveratrol 
decreased the mRNA and protein levels of TNF-? en COX-
2, suggesting that an anti-inflammatory mechanism underlies 
the protective effects of resveratrol. The effects of resveratrol 
on the 6-OHDA injury in rats were further studied by Khan 
et al., [177]. Instead of posttreatment, they administered 
resveratrol (20 mg/kg) for two weeks prior to the induced 
injury. They discovered that resveratrol was not only capable 
of protecting neurons, but also of elevating the activity of 
antioxidant enzymes and decreasing the levels of 
thiobarbituric acid reactive substances (TBARS), protein 
carbonyl (PC) and phospholipase A2 (PA2), providing 
evidence for a possible antioxidant property of resveratrol as 
well. 
 Although these four studies showed encouraging results, 
there is a lack of evidence for the effects of resveratrol in 
animals other than rodents. Also, to date only MPTP and 6-
OHDA injury models have been investigated. Therefore, 
further experimental investigations are needed to determine 
if the positive results from these models can be replicated in 
other injury models and animals, before resveratrol can be 
tested in clinical PD trials. In addition, due to its abundance 
in red wine, it is appealing to investigate the difference 
between red wine drinkers and non-red wine drinkers in 
association with the risk of developing PD. To our 
knowledge, such an epidemiological study has not been 
performed. 
DISCUSSION AND FUTURE DIRECTIONS 
 There is an urgent need for novel neuroprotective 
therapies for the fast growing number of patients diagnosed 
with PD. This review summarizes the in vivo preclinical data 
of neuroprotective compounds for the treatment of PD and 
provides a starting point for upcoming research. However, it 
must be noted, that this is not an extensive list of all 
currently known neuroprotective therapies. For example, 
therapies that require surgery or therapies in various stages 
of development are not considered. Moreover, due to the 
substantial differences in animals, utilized dose, injury 
model and severity, dose regime and endpoints it is quite 
difficult to draw firm conclusions as to which substance has 
the most potential for neuroprotection. 
 The results of this study show that some substances (e.g. 
nicotine or melatonin) have been investigated more 
extensively than others and have been effective in several 
injury models, whereas others have only recently been 
identified as neuroprotective (Table 1). It must be stressed 
that the frequency of published papers is not an indication of 
neuroprotective potency; it merely represents positioning in 
the development process. However, this study also revealed 
some obvious gaps, especially in time windows of efficacy 
and therapeutic dose, which should be addressed in future 
research. Moreover, it is clear that when compounds have 
been shown to be effective in all injury models there will be 
a greater chance that they will succeed in human trials. Since 
the various neurotoxins have distinct mechanisms of action, 
this could have implications for other processes in the 
pathophysiology of PD [178]. It is also possible that some 
neurotoxins can more precisely represent a distinct type of 
PD. However, as long as the underlying pathophysiology 
remains elusive, the predictive value of these models 
continues to be problematic as well [14]. Next to the limited 
value of current clinical trials to determine the 
neuroprotective effect of investigated agents, this constitutes 
an important obstacle in the translation of preclinical data to 
human trials. However, several efforts have been made to 
improve the quality of animal research. It is estimated that 
the current use of neurotoxins will eventually make way for 
transgenic animals or models in which animals more 
specifically represent the biochemical hallmarks of PD [14]. 
Another important translational drawback is the low 
bioavailability in humans of substances like resveratrol, 
EGCG, curcumin and coenzyme Q10 [179-182]. In order to 
address this issue, it is suggested for these substances to 
focus future investigations on pharmacokinetic studies. 
Optimizing the formulation would be of value for the 
bioavailability and stability of the compounds. Such efforts 
have for instance already been made with resveratrol, 
including studies that performed co-administration of 
metabolism inhibitors, the use of less instable analogues and 
the development of nanotechnology based delivery systems 
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[183]. Similar studies could be performed with curcumin, 
EGCG and coenzyme Q10. Results from such studies should 
be used to find superior neuroprotective compounds in the 
Parkinson model. Due to the natural character of these 
compounds (except riluzole) patent protection for a 
neuroprotective application is not very strong, making 
funding of clinical research dependent on government 
funding. 
 The ten identified compounds in this review exhibit 
several modes of action, including anti-oxidative and anti-
inflammatory. Since PD has a multifactorial etiology, an 
interesting question is whether the combination of such 
distinct agents could result in synergistic effects [184], 
which could be investigated in future research. Another 
appealing detail is that most of these compounds represent a 
larger group of familiar compounds that could be 
neuroprotective as well. For instance, caffeine belongs to a 
larger group of A2A receptor antagonists, which as a group 
seems promising [185]. Modifying and fine-tuning such 
agents to maximize their efficacy and minimize side-effects 
could lead to superior patentable agents. 
 Overall, it is clear that there are still some urgent 
questions that need to be addressed to clear the way for 
effective neuroprotective treatments. For instance, there is 
still a high variance in administered doses and it is thus of 
high interest that the optimal dose of every putative 
neuroprotective agent is determined. Specialized, precise 
dose-finding studies could offer the solution to this 
predicament. Also, several compounds have not been tested 
in all available injury models and still lack enough 
preclinical evidence to progress into clinical development. 
Another important topic future research should focus on is 
the fundamental mode of action of specific compounds. 
Improving our knowledge about the underlying mechanisms 
could aid designing novel compounds with enhanced 
efficacy and/or safety. Along this line, we still lack a 
complete picture about the etiology of PD. All research into 
this issue remains of vital importance for the development of 
effective therapies. 
 In conclusion, this study depicts the preclinical data of 
ten promising neuroprotective agents in a clear and 
systematic manner. The results from this study facilitate the 
translation of preclinical data into human trials. While some 
of these compounds have already been tested in clinical use, 
none has been studied in an appropriately designed trial to 
determine a neuroprotective effect. Expecting qualitatively 
better neuroprotection trials, the data from this study provide 
a firm foundation for future research. This offers a better 
chance for the development of novel neuroprotective 
therapies and provides hope for patients suffering from PD. 
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